Pharmacodynamics (PD) describes interactions of drugs with the organisms.
This includes binding of drugs to their targets (which may also be relevant for understanding the PK) and resulting direct or indirect effects. Pharmacodynamics can also relate drug concentration profiles (PK) to clinical endpoints, which usually requires consideration of disease progression. Various modeling approaches are used to either analyze PD or disease progression alone or in combination with PK. Simple models use a sigmoidal function to relate a concentration to its effects (e.g. Hill, IC50, Emax-shape) - here the maximum effect as well as the concentration that corresponds to half the maximum effect are typical curve characteristics. Such approaches can be combined with advanced statistical methods as the effect of a drug is rarely fully deterministic. Inter- individual or inter-occasion differences can be investigated and quantified in such a way see also Modeling Concepts - PK and PD Modeling
It is often not straightforward to transfer or translate such models to new scenarios of application. This, tool can be desirable in order to make predictions. A typical question to answer would be how the curve characteristics is expected to change in the new situation. However, if the model explicitly considers the crucial physiologic and mechanistic aspects, and it is known from independent experiments how these change in certain scenarios, a translation and prediction can become feasible. The level of mechanistic detail needed depends on the particular problem. In certain cases the desired detail might include sophisticated reaction networks. Sometimes these are on their own sufficient to understand relevant PD behavior . Detailed pathway modeling is also a major activity in systems biology in academia. Many excellent reviews are devoted to this topic, which will not be further detailed here.
In other cases or for other questions the PK/PD interaction is important to be considered. Here, PBPK models offer an intuitive framework to couple PK with simple or mechanistic PD models. See  for a recent example.